-
Abed Y, Nehme B, Baz M, Boivin G, 2008: Activity of the neuraminidase inhibitor A-315675 against oseltamivir-resistant influenza neuraminidases of N1 and N2 subtypes[J]. Antiviral Res, 77, 163-166. doi: 10.1016/j.antiviral.2007.08.008
-
Babu Y S, Chand P, Bantia S, Kotian P, Dehghani A, El-Kattan Y, Lin T H, Hutchison T L, Elliott A J, Parker C D, Ananth S L, Horn L L, Laver G W, Montgomery J A, 2000: BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design[J]. J Med Chem, 43, 3482-3486. doi: 10.1021/jm0002679
-
Baz M, Abed Y, McDonald J, Boivin G, 2006: Characterization of multidrug-resistant influenza A/H3N2 viruses shed during 1 year by an immunocompromised child[J]. Clin Infect Dis, 43, 1555-1561. doi: 10.1086/508777
-
Colacino J M, Chirgadze N Y, Garman E, Murti K G, Loncharich R J, Baxter A J, Staschke K A, Laver W G, 1997: A single sequence change destabilizes the influenza virus neuraminidase tetramer[J]. Virology, 236, 66-75. doi: 10.1006/viro.1997.8709
-
Collins P J, Haire L F, Lin Y P, Liu J, Russell R J, Walker P A, Skehel J J, Martin S R, Hay A J, Gamblin S J, 2008: Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants[J]. Nature, 453, 1258-1261. doi: 10.1038/nature06956
-
Crennell S J, Takimoto T, Portner A, Taylor G, 2000: Crystal structure of the multifunctional paramyxovirus hemagglutinin-neuraminidase[J]. Nat Struct Biol, 7, 1068-1074. doi: 10.1038/81002
-
Crennell S J, Garman E F, Laver W G, Vimr E R, Taylor G L, 1993: Crystal structure of a bacterial sialidase (from Salmonella typhimurium LT2) shows the same fold as an influenza virus neuraminidase[J]. Proc Natl Acad Sci U S A, 90, 9852-9856. doi: 10.1073/pnas.90.21.9852
-
de Jong M D, Tran T T, Truong H K, Vo M H, Smith G J, Nguyen V C, Bach V C, Phan T Q, Do Q H, Guan Y, Peiris J S, Tran T H, Farrar J, 2005: Oseltamivir resistance during treatment of influenza A (H5N1) infection[J]. N Engl J Med, 353, 2667-2672. doi: 10.1056/NEJMoa054512
-
DeGoey D A, Chen H J, Flosi W J, Grampovnik D J, Yeung C M, Klein L L, Kempf D J, 2002: Enantioselective synthesis of antiinfluenza compound A-315675[J]. J Org Chem, 67, 5445-5453. doi: 10.1021/jo0162890
-
Godbey W T, Wu K K, Mikos A G, 1999: Poly(ethylenimine) and its role in gene delivery[J]. J Control Release, 60, 149-160. doi: 10.1016/S0168-3659(99)00090-5
-
Gubareva L V, Penn C R, Webster R G, 1995: Inhibition of replication of avian influenza viruses by the neuraminidase inhibitor 4-guanidino-2, 4-dideoxy-2, 3-dehydro-N-acetylneuraminic acid[J]. Virology, 212, 323-330. doi: 10.1006/viro.1995.1489
-
Gubareva L V, Webster R G, Hayden F G, 2001: Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants[J]. Antimicrob Agents Chemother, 45, 3403-3408. doi: 10.1128/AAC.45.12.3403-3408.2001
-
Gubareva L V, Robinson M J, Bethell R C, Webster R G, 1997: Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en[J]. J Virol, 71, 3385-3390.
-
Gubareva L V, Kaiser L, Matrosovich M N, Soo-Hoo Y, Hayden F G, 2001: Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir[J]. J Infect Dis, 183, 523-531. doi: 10.1086/jid.2001.183.issue-4
-
Hata K, Koseki K, Yamaguchi K, Moriya S, Suzuki Y, Yingsakmongkon S, Hirai G, Sodeoka M, von Itzstein M, Miyagi T, 2008: Limited inhibitory effects of oseltamivir and zanamivir on human sialidases[J]. Antimicrob Agents Chemother, 52, 3484-3491. doi: 10.1128/AAC.00344-08
-
Hatakeyama S, Sugaya N, Ito M, Yamazaki M, Ichikawa M, Kimura K, Kiso M, Shimizu H, Kawakami C, Koike K, Mitamura K, Kawaoka Y, 2007: Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors[J]. Jama, 297, 1435-1442.
-
He J, Choe S, Walker R, Di Marzio P, Morgan DO, Landau NR, 1995: Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity[J]. J Virol, 69, 6705-6711.
-
Herlocher M L, Carr J, Ives J, Elias S, Truscon R, Roberts N, Monto A S, 2002: Influenza virus carrying an R292K mutation in the neuraminidase gene is not transmitted in ferrets[J]. Antiviral Res, 54, 99-111. doi: 10.1016/S0166-3542(01)00214-5
-
Herlocher M L, Truscon R, Elias S, Yen H L, Roberts N A, Ohmit S E, Monto A S, 2004: Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets[J]. J Infect Dis, 190, 1627-1630. doi: 10.1086/jid.2004.190.issue-9
-
Hurt A C, Selleck P, Komadina N, Shaw R, Brown L, Barr I G, 2007: Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes[J]. Antiviral Res, 73, 228-231. doi: 10.1016/j.antiviral.2006.10.004
-
Ison M G, Gubareva L V, Atmar R L, Treanor J, Hayden F G, 2006: Recovery of drug-resistant influenza virus from immunocompromised patients: a case series[J]. J Infect Dis, 193, 760-764. doi: 10.1086/jid.2006.193.issue-6
-
Kati W M, Montgomery D, Carrick R, Gubareva L, Maring C, McDaniel K, Steffy K, Molla A, Hayden F, Kempf D, Kohlbrenner W, 2002: in vitro characterization of A-315675, a highly potent inhibitor of A and B strain influenza virus neuraminidases and influenza virus replication[J]. Antimicrob Agents Chemother, 46, 1014-1021. doi: 10.1128/AAC.46.4.1014-1021.2002
-
Kiso M, Mitamura K, Sakai-Tagawa Y, Shiraishi K, Kawakami C, Kimura K, Hayden F G, Sugaya N, Kawaoka Y, 2004: Resistant influenza A viruses in children treated with oseltamivir: descriptive study[J]. Lancet, 364, 759-765. doi: 10.1016/S0140-6736(04)16934-1
-
Le Q M, Kiso M, Someya K, Sakai Y T, Nguyen T H, Nguyen K H, Pham N D, Ngyen H H, Yamada S, Muramoto Y, Horimoto T, Takada A, Goto H, Suzuki T, Suzuki Y, Kawaoka Y, 2005: Avian flu: isolation of drug-resistant H5N1 virus[J]. Nature, 437, 1108-. doi: 10.1038/4371108a
-
Liu J, Xiao H, Lei F, Zhu Q, Qin K, Zhang XW, Zhang XL, Zhao D, Wang G, Feng Y, Ma J, Liu W, Wang J, Gao GF, 2005: Highly pathogenic H5N1 influenza virus infection in migratory birds[J]. Science, 309, 1206-. doi: 10.1126/science.1115273
-
Maring C J, Stoll V S, Zhao C, Sun M, Krueger A C, Stewart K D, Madigan D L, Kati W M, Xu Y, Carrick R J, Montgomery D A, Kempf-Grote A, Marsh K C, Molla A, Steffy K R, Sham H L, Laver W G, Gu Y G, Kempf D J, Kohlbrenner W E, 2005: Structure-based characterization and optimization of novel hydrophobic binding interactions in a series of pyrrolidine influenza neuraminidase inhibitors[J]. J Med Chem, 48, 3980-3990. doi: 10.1021/jm049276y
-
McKimm-Breschkin J, Trivedi T, Hampson A, Hay A, Klimov A, Tashiro M, Hayden F, Zambon M, 2003: Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir[J]. Antimicrob Agents Chemother, 47, 2264-2272. doi: 10.1128/AAC.47.7.2264-2272.2003
-
Potier M, Mameli L, Belisle M, Dallaire L, Melancon SB, 1979: Fluorometric assay of neuraminidase with a sodium (4-methyl umbelliferyl-alpha-D-N-acetylneuraminate) substrate[J]. Anal Biochem, 94, 287-296. doi: 10.1016/0003-2697(79)90362-2
-
Richard M, Deleage C, Barthelemy M, Lin Y P, Hay A, Lina B, Ferraris O, 2008: Impact of influenza A virus neuraminidase mutations on the stability, activity, and sensibility of the neuraminidase to neuraminidase inhibitors[J]. J Clin Virol, 41, 20-24. doi: 10.1016/j.jcv.2007.10.021
-
Russell R J, Haire L F, Stevens D J, Collins P J, Lin Y P, Blackburn G M, Hay A J, Gamblin S J, Skehel J J, 2006: The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design[J]. Nature, 443, 45-49. doi: 10.1038/nature05114
-
Ryan D M, Ticehurst J, Dempsey M H, 1995: GG167 (4-guanidino-2, 4-dideoxy-2, 3-dehydro-N-acetylneuraminic acid) is a potent inhibitor of influenza virus in ferrets[J]. Antimicrob Agents Chemother, 39, 2583-2584. doi: 10.1128/AAC.39.11.2583
-
Stoll V, Stewart K D, Maring C J, Muchmore S, Giranda V, Gu Y G, Wang G, Chen Y, Sun M, Zhao C, Kennedy A L, Madigan D L, Xu Y, Saldivar A, Kati W, Laver G, Sowin T, Sham H L, Greer J, Kempf D, 2003: Influenza neuraminidase inhibitors: structure-based design of a novel inhibitor series[J]. Biochemistry, 42, 718-727. doi: 10.1021/bi0205449
-
Tai C Y, Escarpe P A, Sidwell R W, Williams M A, Lew W, Wu H, Kim C U, Mendel D B, 1998: Characterization of human influenza virus variants selected in vitro in the presence of the neuraminidase inhibitor GS 4071[J]. Antimicrob Agents Chemother, 42, 3234-3241.
-
Taylor G, Garman E, Webster R, Saito T, Laver G, 1993: Crystallization and preliminary X-ray studies of influenza A virus neuraminidase of subtypes N5, N6, N8 and N9[J]. J Mol Biol, 230, 345-348. doi: 10.1006/jmbi.1993.1147
-
von Itzstein M, Wu W Y, Kok G B, Pegg M S, Dyason J C, Jin B, Van Phan T, Smythe M L, White H F, Oliver S W, 1993: Rational design of potent sialidase-based inhibitors of influenza virus replication[J]. Nature, 363, 418-423. doi: 10.1038/363418a0
-
Weinstock D M, Gubareva L V, Zuccotti G, 2003: Prolonged shedding of multidrug-resistant influenza A virus in an immunocompromised patient[J]. N Engl J Med, 348, 867-868. doi: 10.1056/NEJM200302273480923
-
Whitley R J, Hayden F G, Reisinger K S, Young N, Dutkowski R, Ipe D, Mills R G, Ward P, 2001: Oral oseltamivir treatment of influenza in children[J]. Pediatr Infect Dis J, 20, 127-133. doi: 10.1097/00006454-200102000-00002
-
WHO. 2008. Influenza A(H1N1) virus resistance to oseltamivir -2008 influenza season, southern hemisphere. World Health Organization.
-
Woods J M, Bethell R C, Coates J A, Healy N, Hiscox S A, Pearson B A, Ryan D M, Ticehurst J, Tilling J, Walcott S M, a nd, 1993: 4-Guanidino-2, 4-dideoxy-2, 3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro[J]. Antimicrob Agents Chemother, 37, 1473-1479. doi: 10.1128/AAC.37.7.1473
-
Yen H L, Ilyushina N A, Salomon R, Hoffmann E, Webster R G, Govorkova E A, 2007: Neuraminidase inhibitor-resistant recombinant A/Vietnam/1203/04 (H5N1) influenza viruses retain their replication efficiency and pathogenicity in vitro and in vivo[J]. J Virol, 81, 12418-12426. doi: 10.1128/JVI.01067-07
-
Yen H L, Herlocher L M, Hoffmann E, Matrosovich M N, Monto A S, Webster R G, Govorkova E A, 2005: Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility[J]. Antimicrob Agents Chemother, 49, 4075-4084. doi: 10.1128/AAC.49.10.4075-4084.2005
-
Yen H L, Hoffmann E, Taylor G, Scholtissek C, Monto A S, Webster R G, Govorkova E A, 2006: Importance of neuraminidase active-site residues to the neuraminidase inhibitor resistance of influenza viruses[J]. J Virol, 80, 8787-8795. doi: 10.1128/JVI.00477-06